HSGX Research and Charts

HSGX - Histogenics Corp (Healthcare: Biotechnology)

Projected Earnings Date: 2020-02-10 (Delayed quote data 2025-04-17)

Last 0.68	Change ⇑ +0.03 (+0.00%)	Volume 3,490,761
	Open 0.65	High 0.69	Low 0.65

8EMA (Daily) 0.67	40EMA (Daily) 0.66	50EMA (Daily) 0.67	STO (Daily) 48.391	MACD Hist (Daily) 0.003
8EMA (Weekly) 0.681	40EMA (Weekly) 0.87	50EMA (Weekly) 0.90	STO (Weekly) 39.407	MACD Hist (Weekly) 0.024


Company Profile
Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Histogenics operates in two geographic regions: The United States (Massachusetts) and Israel (Tel Aviv). Regenerative medicine technologies encompass a variety of therapeutic approaches, including tissue engineering, cell-based therapies, gene therapy, small molecules and biologics, stem cells and biobanking.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.